COMPARISON OF TC-99M MAG3 AND TC-99M DTPA IN RENAL-TRANSPLANT PATIENTS WITH IMPAIRED RENAL-FUNCTION

被引:35
作者
TAYLOR, A
ZIFFER, JA
ESHIMA, D
机构
关键词
D O I
10.1097/00003072-199006000-00001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Tc-99m mercaptoacetyltriglycine (MAG3) is a new Tc-99m renal agent that compares favorably to 1-131 Hippuran in animal models, normal volunteers, and patients. Based on the fact that Tc-99m MAG3 has a much more rapid clearance than Tc-99m DTPA and a smaller volume of distribution, it was postulated that the image quality of Tc-99m MAG3 studies should be superior to scans obtained using Tc-99m DTPA, particularly in patients with impaired renal function. To test this hypothesis, Tc-99m DTPA and MAG3 images were obtained in three transplant patients during periods of stable but impaired renal function. In one study, the Tc-99m DTPA study was potentially misleading, whereas the Tc-99m MAG3 examination assessed the clinical situation correctly. In all three cases, the Tc-99m MAG3 images were superior.
引用
收藏
页码:371 / 378
页数:8
相关论文
共 19 条
[1]   CLINICAL-EXPERIENCE WITH TC-99M-MAG3, MERCAPTOACETYLTRIGLYCINE, AND A COMPARISON WITH TC-99M-DTPA [J].
ALNAHHAS, AA ;
JAFRI, RA ;
BRITTON, KE ;
SOLANKI, K ;
BOMANJI, J ;
MATHER, S ;
CARROLL, MA ;
ALJANABI, M ;
FRUSCIANTE, V ;
AJDINOWIC, B ;
FIORE, F ;
DEMENA, S ;
NIMMON, CC .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1988, 14 (9-10) :453-462
[2]  
BARBOUR GL, 1976, J NUCL MED, V17, P317
[3]  
BUBECK B, 1988, NUCL MED BIOL, V15, P109
[4]  
COVENEY JR, 1987, J NUCL MED, V28, P1881
[5]  
ESHIMA D, 1987, J NUCL MED, V28, P1180
[7]  
JAFRI RA, 1988, J NUCL MED, V29, P147
[8]  
KLOPPER JF, 1972, J NUCL MED, V8, P77
[9]  
LEE H B, 1988, Journal of Nuclear Medicine, V29, P849
[10]  
NOSCO D L, 1988, Journal of Nuclear Medicine, V29, P801